Segment Reporting Disclosure [Text Block] | 10. Operating Segments In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (a) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available. Our reporting segments are defined as below: TREATMENT SEGMENT reporting includes: - nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and - R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams. SERVICES SEGMENT, which includes: - On-site waste management services to commercial and government customers; - Technical services, which include: o professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering; o integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance; o global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; - Nuclear services, which include: o technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal; o remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; site construction; logistics; transportation; and emergency response; and - A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) of health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation. MEDICAL SEGMENT reporting includes: R&D costs for the new medical isotope production technology from our majority-owned Polish subsidiary, PF Medical. The Medical Segment has not generated any revenue as it continues to be primarily in the R&D stage. All costs incurred for the Medical Segment are reflected within R&D in the accompanying Consolidated Statements of Operations and consist primarily of employee salaries and benefits, laboratory costs, third party fees, and other related costs associated with the development of this new technology. Our reporting segments exclude our corporate headquarters and our discontinued operations (see Note 9 – “Discontinued Operations”) which do not generate revenues. The table below presents certain financial information of our operating segments for the three and six months ended June 30, 2016 and 2015 (in thousands). Segment Reporting for the Quarter Ended June 30, 2016 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 7,985 $ 6,824 — $ 14,809 $ — $ 14,809 Intercompany revenues 6 10 — 16 — — Gross profit 582 1,234 — 1,816 — 1,816 Research and development 120 7 416 543 11 554 Interest income 2 — — 2 29 31 Interest expense (14 ) — — (14 ) (94 ) (108 ) Interest expense-financing fees — — — — (29 ) (29 ) Depreciation and amortization 705 160 — 865 47 912 Segment (loss) income before income taxes (10,557 ) (2) 1,046 (416 ) (9,927 ) (1,374 ) (11,301 ) Income tax (benefit) expense (3,167 ) (2) — — (3,167 ) — (3,167 ) Segment (loss) income (7,390 ) 1,046 (416 ) (6,760 ) (1,374 ) (8,134 ) Expenditures for segment assets 16 4 — 20 — 20 Segment Reporting for the Quarter Ended June 30, 2015 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 11,087 $ 5,267 — $ 16,354 $ — $ 16,354 Intercompany revenues 1 6 — 7 — — Gross profit 3,335 697 — 4,032 — 4,032 Research and development 55 — 432 487 2 489 Interest income 1 — — 1 10 11 Interest expense (11 ) — — (11 ) (129 ) (140 ) Interest expense-financing fees — — — — (56 ) (56 ) Depreciation and amortization 743 190 — 933 10 943 Segment income (loss) before income taxes 2,294 60 (432 ) 1,922 (1,479 ) 443 Income tax expense 36 — — 36 — 36 Segment income (loss) 2,258 60 (432 ) 1,886 (1,479 ) 407 Expenditures for segment assets 138 — — 138 6 144 Segment Reporting for the Six Months Ended June 30, 2016 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 15,189 $ 9,658 — $ 24,847 $ — $ 24,847 Intercompany revenues 10 15 — 25 — — Gross profit 444 1,406 — 1,850 — 1,850 Research and development 226 33 854 1,113 15 1,128 Interest income 2 — — 2 45 47 Interest expense (16 ) — — (16 ) (260 ) (276 ) Interest expense-financing fees — — — — (85 ) (85 ) Depreciation and amortization 1,418 321 — 1,739 57 1,796 Segment (loss) income before income taxes (11,805 ) (2) 322 (854 ) (12,337 ) (2,773 ) (15,110 ) Income tax (benefit) expense (3,130 ) (2) — — (3,130 ) — (3,130 ) Segment (loss) income (8,675 ) 322 (854 ) (9,207 ) (2,773 ) (11,980 ) Expenditures for segment assets 23 4 1 28 — 28 Segment Reporting for the Six Months Ended June 30, 2015 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 20,836 $ 9,119 — $ 29,955 $ — $ 29,955 Intercompany revenues 2 15 — 17 — — Gross profit 4,570 940 — 5,510 — 5,510 Research and development 89 — 827 916 2 918 Interest income 2 — — 2 18 20 Interest expense (34 ) — — (34 ) (233 ) (267 ) Interest expense-financing fees (2 ) — — (2 ) (113 ) (115 ) Depreciation and amortization 1,507 380 — 1,887 22 1,909 Segment income (loss) before income taxes 2,514 (241 ) (827 ) 1,446 (2,981 ) (1,535 ) Income tax expense 71 — — 71 — 71 Segment income (loss) 2,443 (241 ) (827 ) 1,375 (2,981 ) (1,606 ) Expenditures for segment assets 244 13 — 257 8 265 ( 1 ) ( 2 ) |